Skip to main content
. 2013 Sep 6;3(9):e144. doi: 10.1038/bcj.2013.42

Figure 5.

Figure 5

Figure 5

In leukemia xenografts, reduced expression of PKR promotes tumor progression and chemoresistance. Reactivation of the PKR/PP2A signaling axis by FTY720 treatment rescues chemosensitivity. (a) NSG mice were divided into five experiment groups (Sicontrol no treatment, Sicontrol DOX treatment, SiPKR no treatment, SiPKR DOX treatment and SiPKR DOX+FTY720 treatment) and inoculated with REH cells (Sicontrol or SiPKR) carrying luciferase gene followed by corresponding intervention in each group. Tumor progression was monitored by weekly in vivo imaging. (b) Tumor progression is evaluated and compared in untreated groups between mice carrying REH Sicontrol cells and mice carrying REH SiPKR cells. (c) Tumor progression following 5 mg/kg DOX treatment (as described in the Materials and methods section) in mice carrying either Sicontrol or SiPKR cells is evaluated and compared. Mice engrafted with REH SiPKR cells were also treated with same dose of DOX plus 2 mg/kg daily FTY720 for 2 weeks, tumor progression was evaluated and compared with mice carrying same leukemic cells but treated with only DOX. (d) Kaplan–Meier curve of overall survival of mice in each group was plotted. (e) Bone marrow cells from moribund mice carrying leukemia were harvested and stained with both human and mouse CD45 antibody, and the results were analyzed by flow cytometry. (f) Bone marrow cells from moribund mice carrying leukemia were harvested and lysed. PKR expression was evaluated by western blot. *Indicates P<0.05.